HER2-targeting immunocytokine stimulated anti-tumor immune profile and marked efficacy in mouse tumor model

被引：0
|
作者：
Lan, K. H. [1 ]
Tsai, C. L. [2 ]
Kuo, S. H. [1 ]
Lan, K. L. [3 ]
机构：
[1] Natl Taiwan Univ Hosp, Oncol, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Biomed Imaging & Radiol Sci, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Heavy Particles & Radiat Oncol, Taipei, Taiwan
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114695
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB162
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [1] Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model
    Ghaedi, Mojgan
    Golsaz-Shirazi, Forough
    Bahadori, Tannaz
    Khoshnoodi, Jalal
    Mortezagholi, Sahar
    Jeddi-Tehrani, Mahmood
    Amiri, Mohammad Mehdi
    Shokri, Fazel
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2437 - 2450
  • [2] Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model
    Mojgan Ghaedi
    Forough Golsaz-Shirazi
    Tannaz Bahadori
    Jalal Khoshnoodi
    Sahar Mortezagholi
    Mahmood Jeddi-Tehrani
    Mohammad Mehdi Amiri
    Fazel Shokri
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2437 - 2450
  • [3] Superior anti-tumor activity of NC18, a novel HER2-targeting ADC, against enhertu-resistant CDX model
    Zhi, L.
    Sun, B.
    Kan, X.
    Ren, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1477 - S1477
  • [4] BL-M07D1, a novel HER2-targeting ADC, demonstrates potent anti-tumor efficacy in preclinical pharmacodynamic models
    Wan, Weili
    Zhao, Shuwen
    Zhuo, Shi
    Zhang, Yong
    Chen, Lan
    Li, Gangrui
    Khalili, Jahan Salar
    Xiao, Sa
    Yan, Yongqi
    Shen, Xuejiao
    Zhu, Yi
    CANCER RESEARCH, 2023, 83 (07)
  • [5] Increasing Targeting and Efficacy of Anti-Tumor Antibody
    McKetney, Justin
    Kerr, Rebecca
    Collins, Edward J.
    BIOPHYSICAL JOURNAL, 2015, 108 (02) : 629A - 629A
  • [6] DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a
    Lin, S.
    Zhang, Y.
    Li, B.
    Shi, R.
    Qiu, Y.
    Hua, H.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S91 - S91
  • [7] A novel anti-tumor anti-PDL1-IL7 immunocytokine targeting lymphocytes
    Cui, Feifei
    Fang, Lei
    Gu, Haijuan
    Yang, Yuanyuan
    Wang, Zhengyi
    Guo, Bingshi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [8] HER2 TKIs enhance the anti-tumor activity of HER2-targeting CAR-T and CAR-NK cells against NSCLC
    Yang, Yan
    Nilsson, Monique B.
    Poteete, Alissa
    He, Junqin
    Huang, Qian
    Heymach, John V.
    CANCER RESEARCH, 2024, 84 (06)
  • [9] OMX IS A TUMOR MICROENVIRONMENT MODIFIER THAT RESTORES ANTI-TUMOR IMMUNITY AND IMPROVES ANTI-TUMOR EFFICACY BY REDUCING TUMOR HYPOXIA IN INTRACRANIAL GLIOBLASTOMA MOUSE MODEL
    Le Moan, Natacha
    Davis, Tina
    Leung, Philberta
    Ng, Sarah
    Winger, Jonathan
    Cary, Stephen
    Butowski, Nicholas
    Krtolica, Ana
    NEURO-ONCOLOGY, 2018, 20 : 259 - 259
  • [10] Anti-tumor Vaccines in head and neck cancer: Targeting immune responses to the tumor
    Whiteside, Theresa L.
    CURRENT CANCER DRUG TARGETS, 2007, 7 (07) : 633 - 642
12345